glass slides with imprinted 316 overlapping 15 residue peptides corresponding to sars-cov-2 s sequence (JPT Peptide Technologies GmbH)
90
Structured Review
JPT Peptide Technologies GmbH
glass slides with imprinted 316 overlapping 15 residue peptides corresponding to sars-cov-2 s sequence
Glass Slides With Imprinted 316 Overlapping 15 Residue Peptides Corresponding To Sars Cov 2 S Sequence, supplied by JPT Peptide Technologies GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/slide+imprinter/sars+cov+2+peptide+pools/pm35468973-357-13-20
Average 90 stars, based on 1 article reviews
Glass Slides With Imprinted 316 Overlapping 15 Residue Peptides Corresponding To Sars Cov 2 S Sequence, supplied by JPT Peptide Technologies GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/slide+imprinter/sars+cov+2+peptide+pools/pm35468973-357-13-20
Average 90 stars, based on 1 article reviews
glass slides with imprinted 316 overlapping 15 residue peptides corresponding to sars-cov-2 s sequence - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Western Blot:Article Title: S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Article Snippet: Subsequently, the cells were stimulated in the presence of a protein transport inhibitor (Brefeldin A, Biolegend) for 16 hours at 37°C with 2 mg of Article Title: Compositions and methods of mRNA vaccines against novel coronavirus infection Article Snippet: Cells were then stimulated for 72 hours at 37° C. with 2 μg of Article Title: Vaccination against SARS-CoV-2 provides low-level cross-protection against common cold coronaviruses in mouse and non-human primate animal models. Article Snippet: PBMCs were stimulated with either SARS-CoV-2 or Article Title: Neutralizing Antibody and T-Cell Spike Targeted Responses Following Receipt of a Monovalent Omicron JN.1-Adapted mRNA COVID-19 Vaccine in Immunosuppressed and Healthy Individuals. Article Snippet: We evaluated homologous neutralizing antibody (NtAb) and T‐cell responses after receipt of a JN.1‐adapted mRNA vaccine in a mixed population comprising healthy controls (HC) (n= 15), end‐stage chronic kidney disease (CKD) patients (n= 17), and allogeneic hematopoietic stem cell transplant recipients (allo‐HCT) (n= 13).. Most participants (42/45) were SARS‐CoV‐ 2‐experienced at the time of immunological testing.. JN.1‐spike‐binding NtAbs were measured with a vesicular stomatitis virus pseudotype‐based neutralization assay, whereas interferon (IFN)‐γ‐producing spike‐directed CD4 or CD8 T‐cell frequencies were enumerated using flow cytometry for intracellular staining. Article Title: Compositions and methods of mRNA vaccines against novel coronavirus infection Article Snippet: Cells were then stimulated for 16 hours at 37° C. with 2 μg of Article Title: A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection. Article Snippet: Two hundred fifty thousand (250,000) Article Title: S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Article Snippet: Subsequently, the cells were stimulated for 72 hours at 37°C with 2 mg of Article Title: S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Article Snippet: The cells were stimulated for 16 hours at 37°C with 2 mg of Positive Control:Article Title: S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Article Snippet: Subsequently, the cells were stimulated in the presence of a protein transport inhibitor (Brefeldin A, Biolegend) for 16 hours at 37°C with 2 mg of Article Title: Compositions and methods of mRNA vaccines against novel coronavirus infection Article Snippet: Cells were then stimulated for 72 hours at 37° C. with 2 μg of Article Title: Vaccination against SARS-CoV-2 provides low-level cross-protection against common cold coronaviruses in mouse and non-human primate animal models. Article Snippet: PBMCs were stimulated with either SARS-CoV-2 or Article Title: Neutralizing Antibody and T-Cell Spike Targeted Responses Following Receipt of a Monovalent Omicron JN.1-Adapted mRNA COVID-19 Vaccine in Immunosuppressed and Healthy Individuals. Article Snippet: We evaluated homologous neutralizing antibody (NtAb) and T‐cell responses after receipt of a JN.1‐adapted mRNA vaccine in a mixed population comprising healthy controls (HC) (n= 15), end‐stage chronic kidney disease (CKD) patients (n= 17), and allogeneic hematopoietic stem cell transplant recipients (allo‐HCT) (n= 13).. Most participants (42/45) were SARS‐CoV‐ 2‐experienced at the time of immunological testing.. JN.1‐spike‐binding NtAbs were measured with a vesicular stomatitis virus pseudotype‐based neutralization assay, whereas interferon (IFN)‐γ‐producing spike‐directed CD4 or CD8 T‐cell frequencies were enumerated using flow cytometry for intracellular staining. Article Title: Compositions and methods of mRNA vaccines against novel coronavirus infection Article Snippet: Cells were then stimulated for 16 hours at 37° C. with 2 μg of Article Title: A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection. Article Snippet: Two hundred fifty thousand (250,000) Article Title: S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Article Snippet: Subsequently, the cells were stimulated for 72 hours at 37°C with 2 mg of Article Title: S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Article Snippet: The cells were stimulated for 16 hours at 37°C with 2 mg of Negative Control:Article Title: S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Article Snippet: Subsequently, the cells were stimulated in the presence of a protein transport inhibitor (Brefeldin A, Biolegend) for 16 hours at 37°C with 2 mg of Article Title: Compositions and methods of mRNA vaccines against novel coronavirus infection Article Snippet: Cells were then stimulated for 72 hours at 37° C. with 2 μg of Article Title: Vaccination against SARS-CoV-2 provides low-level cross-protection against common cold coronaviruses in mouse and non-human primate animal models. Article Snippet: PBMCs were stimulated with either SARS-CoV-2 or Article Title: Neutralizing Antibody and T-Cell Spike Targeted Responses Following Receipt of a Monovalent Omicron JN.1-Adapted mRNA COVID-19 Vaccine in Immunosuppressed and Healthy Individuals. Article Snippet: We evaluated homologous neutralizing antibody (NtAb) and T‐cell responses after receipt of a JN.1‐adapted mRNA vaccine in a mixed population comprising healthy controls (HC) (n= 15), end‐stage chronic kidney disease (CKD) patients (n= 17), and allogeneic hematopoietic stem cell transplant recipients (allo‐HCT) (n= 13).. Most participants (42/45) were SARS‐CoV‐ 2‐experienced at the time of immunological testing.. JN.1‐spike‐binding NtAbs were measured with a vesicular stomatitis virus pseudotype‐based neutralization assay, whereas interferon (IFN)‐γ‐producing spike‐directed CD4 or CD8 T‐cell frequencies were enumerated using flow cytometry for intracellular staining. Article Title: Compositions and methods of mRNA vaccines against novel coronavirus infection Article Snippet: Cells were then stimulated for 16 hours at 37° C. with 2 μg of Article Title: A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection. Article Snippet: Two hundred fifty thousand (250,000) Article Title: S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Article Snippet: Subsequently, the cells were stimulated for 72 hours at 37°C with 2 mg of Article Title: S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Article Snippet: The cells were stimulated for 16 hours at 37°C with 2 mg of Immunopeptidomics:Article Title: S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Article Snippet: Subsequently, the cells were stimulated in the presence of a protein transport inhibitor (Brefeldin A, Biolegend) for 16 hours at 37°C with 2 mg of Article Title: Compositions and methods of mRNA vaccines against novel coronavirus infection Article Snippet: Cells were then stimulated for 72 hours at 37° C. with 2 μg of Article Title: Vaccination against SARS-CoV-2 provides low-level cross-protection against common cold coronaviruses in mouse and non-human primate animal models. Article Snippet: PBMCs were stimulated with either SARS-CoV-2 or Article Title: Neutralizing Antibody and T-Cell Spike Targeted Responses Following Receipt of a Monovalent Omicron JN.1-Adapted mRNA COVID-19 Vaccine in Immunosuppressed and Healthy Individuals. Article Snippet: We evaluated homologous neutralizing antibody (NtAb) and T‐cell responses after receipt of a JN.1‐adapted mRNA vaccine in a mixed population comprising healthy controls (HC) (n= 15), end‐stage chronic kidney disease (CKD) patients (n= 17), and allogeneic hematopoietic stem cell transplant recipients (allo‐HCT) (n= 13).. Most participants (42/45) were SARS‐CoV‐ 2‐experienced at the time of immunological testing.. JN.1‐spike‐binding NtAbs were measured with a vesicular stomatitis virus pseudotype‐based neutralization assay, whereas interferon (IFN)‐γ‐producing spike‐directed CD4 or CD8 T‐cell frequencies were enumerated using flow cytometry for intracellular staining. Article Title: Compositions and methods of mRNA vaccines against novel coronavirus infection Article Snippet: Cells were then stimulated for 16 hours at 37° C. with 2 μg of Article Title: A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection. Article Snippet: Two hundred fifty thousand (250,000) Article Title: S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Article Snippet: Subsequently, the cells were stimulated for 72 hours at 37°C with 2 mg of Article Title: S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Article Snippet: The cells were stimulated for 16 hours at 37°C with 2 mg of Injection:Article Title: S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Article Snippet: Subsequently, the cells were stimulated in the presence of a protein transport inhibitor (Brefeldin A, Biolegend) for 16 hours at 37°C with 2 mg of Article Title: Compositions and methods of mRNA vaccines against novel coronavirus infection Article Snippet: Cells were then stimulated for 72 hours at 37° C. with 2 μg of Article Title: Vaccination against SARS-CoV-2 provides low-level cross-protection against common cold coronaviruses in mouse and non-human primate animal models. Article Snippet: PBMCs were stimulated with either SARS-CoV-2 or Article Title: Neutralizing Antibody and T-Cell Spike Targeted Responses Following Receipt of a Monovalent Omicron JN.1-Adapted mRNA COVID-19 Vaccine in Immunosuppressed and Healthy Individuals. Article Snippet: We evaluated homologous neutralizing antibody (NtAb) and T‐cell responses after receipt of a JN.1‐adapted mRNA vaccine in a mixed population comprising healthy controls (HC) (n= 15), end‐stage chronic kidney disease (CKD) patients (n= 17), and allogeneic hematopoietic stem cell transplant recipients (allo‐HCT) (n= 13).. Most participants (42/45) were SARS‐CoV‐ 2‐experienced at the time of immunological testing.. JN.1‐spike‐binding NtAbs were measured with a vesicular stomatitis virus pseudotype‐based neutralization assay, whereas interferon (IFN)‐γ‐producing spike‐directed CD4 or CD8 T‐cell frequencies were enumerated using flow cytometry for intracellular staining. Article Title: Compositions and methods of mRNA vaccines against novel coronavirus infection Article Snippet: Cells were then stimulated for 16 hours at 37° C. with 2 μg of Article Title: A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection. Article Snippet: Two hundred fifty thousand (250,000) Article Title: S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Article Snippet: Subsequently, the cells were stimulated for 72 hours at 37°C with 2 mg of Article Title: S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Article Snippet: The cells were stimulated for 16 hours at 37°C with 2 mg of Expressing:Article Title: S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Article Snippet: Subsequently, the cells were stimulated in the presence of a protein transport inhibitor (Brefeldin A, Biolegend) for 16 hours at 37°C with 2 mg of Article Title: Compositions and methods of mRNA vaccines against novel coronavirus infection Article Snippet: Cells were then stimulated for 72 hours at 37° C. with 2 μg of Article Title: Vaccination against SARS-CoV-2 provides low-level cross-protection against common cold coronaviruses in mouse and non-human primate animal models. Article Snippet: PBMCs were stimulated with either SARS-CoV-2 or Article Title: Neutralizing Antibody and T-Cell Spike Targeted Responses Following Receipt of a Monovalent Omicron JN.1-Adapted mRNA COVID-19 Vaccine in Immunosuppressed and Healthy Individuals. Article Snippet: We evaluated homologous neutralizing antibody (NtAb) and T‐cell responses after receipt of a JN.1‐adapted mRNA vaccine in a mixed population comprising healthy controls (HC) (n= 15), end‐stage chronic kidney disease (CKD) patients (n= 17), and allogeneic hematopoietic stem cell transplant recipients (allo‐HCT) (n= 13).. Most participants (42/45) were SARS‐CoV‐ 2‐experienced at the time of immunological testing.. JN.1‐spike‐binding NtAbs were measured with a vesicular stomatitis virus pseudotype‐based neutralization assay, whereas interferon (IFN)‐γ‐producing spike‐directed CD4 or CD8 T‐cell frequencies were enumerated using flow cytometry for intracellular staining. Article Title: Compositions and methods of mRNA vaccines against novel coronavirus infection Article Snippet: Cells were then stimulated for 16 hours at 37° C. with 2 μg of Article Title: A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection. Article Snippet: Two hundred fifty thousand (250,000) Article Title: S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Article Snippet: Subsequently, the cells were stimulated for 72 hours at 37°C with 2 mg of Article Title: S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Article Snippet: The cells were stimulated for 16 hours at 37°C with 2 mg of Control:Article Title: S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Article Snippet: Subsequently, the cells were stimulated in the presence of a protein transport inhibitor (Brefeldin A, Biolegend) for 16 hours at 37°C with 2 mg of Article Title: Compositions and methods of mRNA vaccines against novel coronavirus infection Article Snippet: Cells were then stimulated for 72 hours at 37° C. with 2 μg of Article Title: Vaccination against SARS-CoV-2 provides low-level cross-protection against common cold coronaviruses in mouse and non-human primate animal models. Article Snippet: PBMCs were stimulated with either SARS-CoV-2 or Article Title: Neutralizing Antibody and T-Cell Spike Targeted Responses Following Receipt of a Monovalent Omicron JN.1-Adapted mRNA COVID-19 Vaccine in Immunosuppressed and Healthy Individuals. Article Snippet: We evaluated homologous neutralizing antibody (NtAb) and T‐cell responses after receipt of a JN.1‐adapted mRNA vaccine in a mixed population comprising healthy controls (HC) (n= 15), end‐stage chronic kidney disease (CKD) patients (n= 17), and allogeneic hematopoietic stem cell transplant recipients (allo‐HCT) (n= 13).. Most participants (42/45) were SARS‐CoV‐ 2‐experienced at the time of immunological testing.. JN.1‐spike‐binding NtAbs were measured with a vesicular stomatitis virus pseudotype‐based neutralization assay, whereas interferon (IFN)‐γ‐producing spike‐directed CD4 or CD8 T‐cell frequencies were enumerated using flow cytometry for intracellular staining. Article Title: Compositions and methods of mRNA vaccines against novel coronavirus infection Article Snippet: Cells were then stimulated for 16 hours at 37° C. with 2 μg of Article Title: A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection. Article Snippet: Two hundred fifty thousand (250,000) Article Title: S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Article Snippet: Subsequently, the cells were stimulated for 72 hours at 37°C with 2 mg of Article Title: S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Article Snippet: The cells were stimulated for 16 hours at 37°C with 2 mg of Derivative Assay:Article Title: S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Article Snippet: Subsequently, the cells were stimulated in the presence of a protein transport inhibitor (Brefeldin A, Biolegend) for 16 hours at 37°C with 2 mg of Article Title: Compositions and methods of mRNA vaccines against novel coronavirus infection Article Snippet: Cells were then stimulated for 72 hours at 37° C. with 2 μg of Article Title: Vaccination against SARS-CoV-2 provides low-level cross-protection against common cold coronaviruses in mouse and non-human primate animal models. Article Snippet: PBMCs were stimulated with either SARS-CoV-2 or Article Title: Neutralizing Antibody and T-Cell Spike Targeted Responses Following Receipt of a Monovalent Omicron JN.1-Adapted mRNA COVID-19 Vaccine in Immunosuppressed and Healthy Individuals. Article Snippet: We evaluated homologous neutralizing antibody (NtAb) and T‐cell responses after receipt of a JN.1‐adapted mRNA vaccine in a mixed population comprising healthy controls (HC) (n= 15), end‐stage chronic kidney disease (CKD) patients (n= 17), and allogeneic hematopoietic stem cell transplant recipients (allo‐HCT) (n= 13).. Most participants (42/45) were SARS‐CoV‐ 2‐experienced at the time of immunological testing.. JN.1‐spike‐binding NtAbs were measured with a vesicular stomatitis virus pseudotype‐based neutralization assay, whereas interferon (IFN)‐γ‐producing spike‐directed CD4 or CD8 T‐cell frequencies were enumerated using flow cytometry for intracellular staining. Article Title: Compositions and methods of mRNA vaccines against novel coronavirus infection Article Snippet: Cells were then stimulated for 16 hours at 37° C. with 2 μg of Article Title: A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection. Article Snippet: Two hundred fifty thousand (250,000) Article Title: S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Article Snippet: Subsequently, the cells were stimulated for 72 hours at 37°C with 2 mg of Article Title: S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines. Article Snippet: The cells were stimulated for 16 hours at 37°C with 2 mg of |